Differential T cell reactivity to seasonal coronaviruses and SARS-CoV-2 in community and health care workers - da Silva Antunes, Ricardo; Pallikkuth, Suresh; Williams, Erin; Yu, Esther Dawen; Mateus, Jose; Quiambao, Lorenzo; Wang, Eric; Rawlings, Stephen A.; Stadlbauer, Daniel; Jiang, Kaijun; Amanat, Fatima; Arnold, David; et al. (medRxiv, 2021)
Herein we measured CD4+ T cell responses against common cold corona (CCC) viruses and SARS-CoV-2 in high-risk health care workers (HCW) and community controls. We observed higher levels of CCC reactive T cells in SARS-CoV-2 seronegative HCW compared to community donors, consistent with potential higher occupational exposure of HCW to CCC. We further show that SARS-CoV-2 reactivity of seronegative HCW was higher than community controls and correlation between CCC and SARS-CoV-2 responses is consistent with cross-reactivity and not associated with recent in vivo activation. Surprisingly, CCC reactivity was decreased in SARS-CoV-2 infected HCW, suggesting that exposure to SARS-CoV-2 might interfere with CCC responses, either directly or indirectly. This result was unexpected, but consistently detected in independent cohorts derived from Miami and San Diego.Competing Interest StatementA.S. is a consultant for Gritstone, Flow Pharma, Merck, Epitogenesis, Gilead and Avalia. S.C. is a consultant for Avalia.Funding StatementThis work was funded by the NIH NIAID under awards AI142742 (Cooperative Centers for Human Immunology) (A.S., S.C.), NIH contract Nr. 75N9301900065 (D.W., A.S.), U01 AI141995-03 (A.S., B.P.), and U01 CA260541-01 (D.W). This work was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C (FK, for reagent generation), Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051 (FK, for reagent generation), NIH NIA R01 AG068110-01A1 (S.G.P, S.P), Miami CTSI emerging disease proposal (D.J., S.G.P, S.P.), University of Miami Institutional Support and the generous support of the JPB foundation, the Open Philanthropy Project (#2020-215611) and other philanthropic donations.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Seronegative donors samples were obtained from local healthy unexposed adults in an anonymous fashion and protocols approved by the institutional review boards (IRB) of the La Jolla Institute (IRB#:VD-112). Seropositive donors samples were either obtained at a UC San Diego Health clinic under the approved IRB protocols of the University of California, San Diego (UCSD; 200236X), recruited at the La Jolla Institute under IRB approved (LJI; VD-214)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo relevant data needs to be submitted to a public repository